ArticleFrontiers in immunology2021
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Correlating obstructive sleep apnea and lung adenocarcinoma using hub gene signatures and molecular mechanisms.Discover oncology · 2026Article
- Multi-omics profiling revealsTranslational lung cancer research · 2026Article
- Concurrent mutations in multiple tumor suppressor genes correlate with adverse prognosis in stage I lung adenocarcinoma patients.Journal of thoracic disease · 2025Article
- Review
- Identifying the key hub genes linked with lung squamous cell carcinoma by examining the differentially expressed and survival genes.Molecular genetics and genomics : MGG · 2024Article
- Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB).Translational lung cancer research · 2024Article
- Article
- Prognostic and predictive impact of molecular tumor burden index in non-small cell lung cancer patients.Thoracic cancer · 2023Article
- Characterization of virus-mediated autoimmunity and the consequences for pathological process in patients with systemic lupus erythematosus.Clinical rheumatology · 2023Article
- Classification prediction of early pulmonary nodes based on weighted gene correlation network analysis and machine learning.Journal of cancer research and clinical oncology · 2023Article
- FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway.International journal of biological sciences · 2023Article
- Arachidonate 15-lipoxygenase type B: Regulation, function, and its role in pathophysiology.Frontiers in pharmacology · 2022Review
- Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways.Frontiers in immunology · 2022Review
- ZNF143 Expression is Associated with COPD and Tumor Microenvironment in Non-Small Cell Lung Cancer.International journal of chronic obstructive pulmonary disease · 2022Article
- Expression of Lipid-Metabolism Genes Is Correlated With Immune Microenvironment and Predicts Prognosis in Osteosarcoma.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancers (NSCLCs) are largely classified into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), which have different therapeutic options according to its molecular profiles and immune checkpoint expression, especially PD-L1, which is a suppressive factor in the tumor microenvironment. The tumor microenvironment can be altered by the genomic mutations on specific innate immune genes as well as tumor suppressor genes, so it is essential to comprehend the association between tumor microenvironment and tumor suppressor genes to discover the promising immunotherapeutic strategy to overcome the resistance of immune check point blockade. In this study, we aimed to analyze how the somatic mutations in tumor suppressor genes affect the tumor immune microenvironment through a comprehensive analysis of mutational profiling on the representative tumor suppressor genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.